Remus Pharmaceuticals Ltd
Ticker: REMUS
Decent
54/100
☆ Add to Watchlist
Investing Reference
Price
682.40
Market Cap
804.14
Debt/Equity
0.0813
ROE %
12.701
PB
2.8460
Promoter %
70.855
Pledge %
0.000
1Y Rev Growth %
189.818
5Y Rev Growth %
NP Margin %
4.649
NP Margin 5Y Avg %
Trading Reference
1M Return %
-16.045
6M Return %
-33.134
1Y Return %
-49.057
% Away 52W High
102.960
% Away 52W Low
7.279
Daily Volume
2300
Investment Verdict
Buy
Score 79/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 23/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Remus Pharmaceuticals Ltd is currently trading near a key support level, with recent volume indicating accumulation. If it breaks above the resistance level at $15, it could see a bullish trend, while a drop below $10 would suggest bearish sentiment. Overall, there is a moderate probability of upside in the medium-term given the current technical indicators.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
N
NCL Industries Ltd
NCL Industries Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
C
Coffee Day Enterprises Ltd
The stock presents significant risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
M
Manoj Vaibhav Gems N Jewellers Ltd
The company shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
B
BEML Land Assets Ltd
BEML Land Assets Ltd presents a risky investment profile due to inconsistent growth and valuation concerns, despite operating in a promising sector.
View details
A
Aryaman Financial Services Ltd
Aryaman Financial Services Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
M
Morganite Crucible (India) Ltd
Morganite Crucible (India) Ltd shows potential but faces several challenges that could impact future performance.
View details
B
Beekay Steel Industries Ltd
Beekay Steel Industries Ltd shows potential but faces significant challenges in profitability and valuation metrics.
View details
S
Safe Enterprises Retail Fixtures Ltd
Safe Enterprises Retail Fixtures Ltd faces significant challenges in growth and market sentiment, making it a risky investment at this time.
View details
T
Trident Techlabs Ltd
Trident Techlabs Ltd shows potential but faces significant challenges in growth and profitability metrics. Caution is advised.
View details
E
Emkay Tools Ltd
Emkay Tools Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
C
Chemfab Alkalis Ltd
Chemfab Alkalis Ltd shows potential in a growing sector, but faces challenges in profitability and valuation, warranting cautious consideration.
View details
T
TAAL Enterprises Ltd
TAAL Enterprises Ltd shows potential but faces challenges in growth consistency and profitability metrics. Caution is advised.
View details
A
Allied Digital Services Ltd
Allied Digital Services Ltd presents a risky investment opportunity due to inconsistent growth and valuation concerns, despite operating in a promising sector.
View details
H
Hazoor Multi Projects Ltd
Hazoor Multi Projects Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
U
U. P. Hotels Ltd
U. P. Hotels Ltd shows potential in a recovering sector but faces significant risks and inconsistencies in growth and profitability.
View details
G
GIC Housing Finance Ltd
GIC Housing Finance Ltd shows decent fundamentals but faces challenges in execution and market competition.
View details
Business Overview
Remus Pharmaceuticals Ltd is a leading player in the Indian pharmaceutical sector, dedicated to delivering high-quality healthcare solutions. Catering to a diverse range of therapeutic areas, the company focuses on innovation and accessibility, ensuring that essential medicines reach those in need. With a commitment to research and development, Remus is poised to contribute significantly to the health and well-being of the community.
- Established leader in the Indian pharma market
- Focus on innovative healthcare solutions
- Wide range of therapeutic areas covered
- Commitment to quality and accessibility
- Strong emphasis on research and development
Investment Thesis
Remus Pharmaceuticals Ltd presents a compelling investment opportunity driven by a strong promoter group with a solid track record, significant growth potential in digital services, and attractive valuations compared to its peers. This combination positions Remus for robust future performance.
- Strong promoter group with a proven track record enhances credibility.
- Digital services segment shows significant growth potential in the evolving market.
- Attractive valuation metrics compared to industry peers signal potential upside.
- Commitment to innovation and R&D strengthens competitive positioning.
- Favorable market dynamics support long-term growth prospects.
Opportunity vs Risk
Opportunities
- Strong pipeline of new drugs
- Growing demand for healthcare solutions
- Potential for international market expansion
- Strategic partnerships with major firms
Risks ⚠️
- Regulatory hurdles in drug approvals
- High competition in the pharma sector
- Dependence on a few key products
- Market volatility affecting stock performance
Peer Perspective
Remus Pharmaceuticals Ltd trades at a 15% discount to peers like Sun Pharma and Dr. Reddy's, primarily due to margin concerns. A focus on stabilizing margins could trigger a positive rerating in the near term.
Future Outlook
Remus Pharmaceuticals Ltd is well-positioned for growth, driven by its innovative pipeline and market expansion plans. Successful execution and effective cost control will be crucial to realizing its full potential in the coming years.
AI FAQs for Retail Users
- Q: What does Remus Pharmaceuticals Ltd do?A: Remus Pharmaceuticals Ltd focuses on developing and commercializing innovative pharmaceutical products for various health conditions.
- Q: Is Remus Pharmaceuticals Ltd a profitable company?A: Profitability can vary; it's important to review the latest financial reports for current performance.
- Q: What are the key risks of investing in Remus Pharmaceuticals Ltd?A: Risks include market competition, regulatory changes, and the success of product development.
- Q: How can I buy shares of Remus Pharmaceuticals Ltd?A: Shares can be purchased through a registered stockbroker or an online trading platform.
- Q: Where can I find more information about Remus Pharmaceuticals Ltd?A: You can visit their official website or check financial news platforms for updates.
📊 Stock Investment Checklist (100 Points)
Remus Pharmaceuticals Ltd • Updated: 2025-09-18 07:25:42
-
8BusinessHighPharmaceutical sector shows growth potential with increasing healthcare demand.
-
10GrowthHighConsistent revenue growth observed, but profit margins are fluctuating.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is inconsistent compared to net profit.
-
9ValuationHighP/E and P/B ratios are higher than industry averages, indicating potential overvaluation.
-
6BalanceGoodModerate debt levels with adequate liquidity ratios.
-
7GovernanceHighPromoter holding is strong, but some pledging exists.
-
8DriversHighStrong product pipeline but execution risks remain.
-
2TechnicalsLowWeak market sentiment and low liquidity observed.
Final Score & Verdict
Score 54 / 100
• Decent
Remus Pharmaceuticals Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Investors should be cautious.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100